What is ABOS's current stock price?

As of now, ABOS is trading at $1.55, with a daily change of -6.63%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

ABOS Stock Analysis & IQ Rating | Acumen Pharmaceutica

ABOS

Acumen Pharmaceutica

$1.55

-$0.11 | -6.63%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

alert Latest Updates

TopRated Yesterday at 11:11

Perspective Therapeutics stands out with one of the most aggressive upside projections of the day as B. Riley Securities reaffirmed a Buy rating alongside a staggering 506.6% implied upside. The company continues advanci...

ABOS Stock IQ

Login to see Acumen Pharmaceutica (ABOS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

ABOS Target Price

Login to display

Strengths

ABOS Rewards

Earnings are forecast to grow

ABOS Rewards

Trading below its fair value

Chart

$1.98 (-21.72%)

$1.51 (+2.65%)

$1.12 (+38.39%)

$2.35 (-34.04%)

1year

6month

3month

1month

ABOS Risk Level

ABOS has Medium risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Price under $5

Low volume

High volatilty

Medium

LOW

HIGH

ABOS Analysts Opinion

ABOS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

ABOS Analysts Opinion

ABOS Analysts opinion is negative and it remained unchanged from the past 3 months

ABOS Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

95%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NA

83%

ABOS Street Sentiment

ABOS Street Sentiment is extremely bullish and have positive views on the near-term outlook

ABOS Performance Sentiment

Sentiments overview associated with ABOS events and the stock performance.

95%

5%

Positive

Negative

19 out of 20
events present

1 out of 20
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$1.73

Resistance
Price

$1.72

Current Price Range

$2.25

Show methods +

ABOS Latest Analysis +

B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation. Fintel reports that on November 18 2025 B of A Securities maintained coverage of Acumen Pharmaceuticals (NasdaqGS:ABOS) with a Buy recommendation. Analyst Price Forecast Suggests 335.76% Upside

Today

$1.55 | -6.63%

Rating

Arbe Announces Q3 2025 Financial Results. Ltd. (NASDAQ:) (TASE: ARBE) (".Arbe". ".we". ".our". and the ".Company".) a global leader in perception radar solutions today announced its financial results and provided an investor update for its third quarter ending Recent HighlightsA major European OEM is expected to announce a strategic program award in the near future and management believes Arbe'.s radar chipset is in the lead to be selected as the key enabler of its ey

Mon Nov 17, 2025

$1.58 | -8.67%

Activity

Potential

Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) Q3 2025 Earnings Call Transcript. Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) Q3 2025 Earnings Call Transcript November 12 2025 Acumen Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.43668 expectations were $-0.63. Operator: Good day and welcome to the Acumen Pharma Third Quarter 2025 Conference Call and Webcast. [Operator Instructions] As a reminder this call may be recorded. I would now like [….]

Thu Nov 13, 2025

$1.81 | -7.18%

Earnings

Becton Dickinson Sees High Single-Digit Profit Growth Ahead Plans Share Buybacks From Waters Deal. ) reported fourth-quarter adjusted earnings of $3.96 beating .The company reported third-quarter 2025 sales of $5.89 billion slightly below the consensus of $5.90 billion.Revenues increased 8.3% as reported 7% adjusted FXN and 3.9% organic.Medical segment sales increased 11.2% . Medication Delivery Solutions’. performance reflects strong growth led by Vascular Access Management partially offse

Thu Nov 6, 2025

$1.90 | -6.40%

Potential

PharmaCorp Announces C$15 Million Bought Deal Public Offering. SASKATOON Saskatchewan Nov. 05 2025 (GLOBE NEWSWIRE) -- PharmaCorp Rx Inc. (PharmaCorp or the Company) (TSXV:) is pleased to announce that it has entered into an agreement with a syndicate of underwriters (the Underwriters) co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Limited pursuant to which the Underwriters have agreed to purchase on a bought deal basis 35.7 million units (the Units) in the capital of the

Wed Nov 5, 2025

$2.03 | +4.64%

Activity

Potential

FAQ About ABOS Stock Insights

What is ABOS current stock price?

What are ABOS stock strengths?

What is ABOS Risk Level?

What is ABOS market cap and volume?

What is ABOS current Stock IQ?

Should I buy ABOS stock right now?

Is ABOS a Strong Buy right now?

What does a 'Strong Buy' rating mean for ABOS?

What does a 'Strong Sell' rating mean for ABOS?

What factors influence ABOS's Stock IQ?

Explore our ABOS Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored ABOS Stock Strategies
Effective Risk Management

FIND US ON

Receive our ABOS Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

ABOS

Acumen Pharmaceutica

Current Price

$1.55

-$0.11 | -6.63%

52W High

$2.47

MKT CAP

$92.07M

52W Low

$0.86

VOL

$127.04K

P/E Ratio

N/A

AVG VOL

$326.36K

RSI

36.04

TREND

Sideways

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

ABOS Rewards

Earnings are forecast to grow

ABOS Rewards

Trading below its fair value

ABOS Stock IQ

Login to unlock Acumen Pharmaceutica (ABOS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$1.98 (-21.72%)

$1.51 (+2.65%)

$1.12 (+38.39%)

$2.35 (-34.04%)

1year

6month

3month

1month

ABOS Analysts Opinion

ABOS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

ABOS Analysts Opinion

ABOS Analysts opinion is negative and it remained unchanged from the past 3 months

ABOS Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

95%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NA

83%

ABOS Street Sentiment

ABOS Street Sentiment is extremely bullish and have positive views on the near-term outlook

ABOS Risk Level

ABOS has Medium risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Price under $5

Low volume

High volatilty

Medium

LOW

HIGH

ABOS Performance Sentiment

Sentiments overview associated with ABOS events and the stock performance.

95%

5%

Positive

Negative

19 out of 20
events present

1 out of 20
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$1.73

Resistance
Price

$1.72

Current Price Range

$2.25

Show methods +

ABOS Latest Analysis

TopRated Yesterday at 11:11

Perspective Therapeutics stands out with one of the most aggressive upside projections of the day as B. Riley Securities reaffirmed a Buy rating alongside a staggering 506.6% implied upside. The company continues advanci...

Discover ABOS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of ABOS. We're here to help you make informed investment decisions today.

FIND US ON

Receive our ABOS Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

ABOS Stock trends

ABOS Stock performance

ABOS Stock analysis

ABOS investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing ABOS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing ABOS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

ABOS Stock Analysis & IQ Rating | Acumen Pharmaceutica

ABOS Stock IQ

ABOS Target Price

ABOS Risk Level

ABOS Analysts Opinion

ABOS Street Sentiment

ABOS Performance Sentiment

Technical Price Levels

Explore our ABOS Stock insights

Receive our ABOS Daily Alerts

ABOS Stock IQ

ABOS Street Sentiment

ABOS Risk Level

Technical Price Levels

Discover ABOS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of ABOS. We're here to help you make informed investment decisions today.

Receive our ABOS Daily Alerts

ABOS Runner Alarm